GTX-102

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Angelman Syndrome

Conditions

Angelman Syndrome

Trial Timeline

Feb 24, 2020 → Jan 8, 2025

NCT ID

NCT04259281

About GTX-102

GTX-102 is a phase 1/2 stage product being developed by Ultragenyx Pharmaceutical for Angelman Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04259281. Target conditions include Angelman Syndrome.

What happened to similar drugs?

0 of 3 similar drugs in Angelman Syndrome were approved

Approved (0) Terminated (0) Active (3)

🔄ION582 + PlaceboIonis PharmaceuticalsPhase 3

🔄GTX-102Ultragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07157254	Phase 2	Recruiting	Oct 13, 2025	Jan 1, 2030	Angelman Syndrome
NCT06617429	Phase 3	Active	Dec 3, 2024	Nov 1, 2027	Angelman Syndrome
NCT06415344	Phase 3	Recruiting	Jul 31, 2024	Feb 1, 2029	Angelman Syndrome
NCT04259281	Phase 1/2	Completed	Feb 24, 2020	Jan 8, 2025	Angelman Syndrome

Competing Products

9 competing products in Angelman Syndrome

See all competitors

Product	Company	Stage	Hype Score
RO7248824	Roche	Phase 1	29
RO7248824	Roche	Phase 1	29
Alogabat	Roche	Phase 2	35
ION582	Ionis Pharmaceuticals	Phase 1/2	36
ION582 + Placebo	Ionis Pharmaceuticals	Phase 3	44
GTX-102	Ultragenyx Pharmaceutical	Phase 3	38
GTX-102	Ultragenyx Pharmaceutical	Phase 3	41
GTX-102	Ultragenyx Pharmaceutical	Phase 2	36
NNZ-2591	Neuren Pharmaceuticals	Phase 2	29